Rhumbline Advisers Sage Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 84,355 shares of SAGE stock, worth $550,838. This represents 0.0% of its overall portfolio holdings.
Number of Shares
84,355
Previous 87,323
3.4%
Holding current value
$550,838
Previous $474,000
47.26%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding SAGE
# of Institutions
217Shares Held
49.9MCall Options Held
220KPut Options Held
312K-
Black Rock Inc. New York, NY5.22MShares$34.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$33.2 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$29.2 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$17.8 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$13.6 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $388M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...